Advertisement

Topics

Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly ...

12:15 EST 13 Nov 2017 | BioMedReports - Blog

 Expert Advisory Board Endorses Randomized Phase I/II Trial in Newly Diagnosed 
Stage III and IV Ovarian Cancer

GEN-1 Immunotherapy to Enter Phase I/II Clinical Study in the First Half of 2018
Following a Phase IB Trial Demonstrating 100% Disease Control, 86% Objective Response Rate
and 86% R0 & R1 Surgical Resection Rate in All Patients Treated

LAWRENCEVILLE, N.J., Nov. 13, 2017 (GLOBE NEWSWIRE)

Read more...

Original Article: Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly ...

NEXT ARTICLE

More From BioPortfolio on "Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly ..."

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women.  Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...